{
    "clinical_study": {
        "@rank": "166",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04341389"
        },
        "id_info": {
            "org_study_id": "JSVCT089",
            "nct_id": "NCT04341389"
        },
        "brief_title": "A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)",
        "acronym": "CTII-nCoV",
        "official_title": "A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China",
                "agency_class": "Other"
            },
            "collaborator": [
                {
                    "agency": "CanSino Biologics Inc.",
                    "agency_class": "Industry"
                },
                {
                    "agency": "Jiangsu Province Centers for Disease Control and Prevention",
                    "agency_class": "Other"
                },
                {
                    "agency": "Hubei Provincial Center for Disease Control and Prevention",
                    "agency_class": "Other"
                }
            ]
        },
        "source": "Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in\n      healthy adults above 18 years of age. This clinical trial is designed to evaluate the\n      immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of\n      SARS-CoV-2."
        },
        "detailed_description": {
            "textblock": "This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in\n      healthy adults above 18 years of age,inclusive, who meet all eligibility criteria. This\n      clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which\n      encodes for a full-length spike (S) protein of SARS-CoV-2. 500 subjects will be enrolled, 250\n      subjects in middle-dose vaccine group, 125 subjects in low-dose and placebo group,\n      respectively. Immunogenicity will be tested on days 0, 14, 28 and 6 months after vaccination"
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 12, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "January 31, 2021"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "January 31, 2021"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Crossover Assignment",
            "primary_purpose": "Prevention",
            "masking": "Double (Participant, Investigator)"
        },
        "primary_outcome": [
            {
                "measure": "Occurrence of adverse reactions",
                "time_frame": "0-14 days post vaccination"
            },
            {
                "measure": "Anti SARS-CoV-2 S antibody response(ELISA)",
                "time_frame": "28 days post vaccination"
            },
            {
                "measure": "Neutralizing antibody response to SARS-CoV-2",
                "time_frame": "28 days post vaccination"
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Occurrence of adverse events",
                "time_frame": "0-28 days post vaccination"
            },
            {
                "measure": "Occurrence of serious adverse reaction",
                "time_frame": "0-6 months post vaccination"
            },
            {
                "measure": "Anti SARS-CoV-2 S antibody response(ELISA)",
                "time_frame": "14 days, 6 months post vaccination"
            },
            {
                "measure": "Neutralizing antibody response to SARS-CoV-2",
                "time_frame": "6 months post vaccination"
            },
            {
                "measure": "Neutralizing antibody response to Ad5-vector",
                "time_frame": "28 days, 6 months post vaccination"
            }
        ],
        "number_of_arms": "3",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "500"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "Arm 1",
                "arm_group_type": "Active Comparator",
                "description": "1\u00d710^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0"
            },
            {
                "arm_group_label": "Arm 2",
                "arm_group_type": "Active Comparator",
                "description": "5\u00d710^110vp of Ad5-nCoV administered through 0.5mL intramuscular injection in the deltoid muscle on Day 0"
            },
            {
                "arm_group_label": "Arm 3",
                "arm_group_type": "Placebo Comparator",
                "description": "Placebo administered through 0.5mL intramuscular injection in the deltoid muscle on Day 0"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Biological",
                "intervention_name": "Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)",
                "description": "Intramuscular injection",
                "arm_group_label": [
                    "Arm 1",
                    "Arm 2"
                ],
                "other_name": "Ad5-nCoV"
            },
            {
                "intervention_type": "Other",
                "intervention_name": "Placebo",
                "description": "Intramuscular injection",
                "arm_group_label": "Arm 3",
                "other_name": "Control"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 18 and 60 years.\n\n          -  Able to understand the content of informed consent and willing to sign the informed\n             consent\n\n          -  Able and willing to complete all the secluded study process during the whole 6 months\n             study follow-up period.\n\n          -  Negative in HIV diagnostic test.\n\n          -  Negative in serum antibodies (IgG and IgM) screening of COVID-19.\n\n          -  Axillary temperature \u226437.0\u00b0C.\n\n          -  The BMI index is 18.5-30.0.\n\n          -  General good health as established by medical history and physical examination.\n\n        Exclusion Criteria:\n\n          -  Family history of seizure, epilepsy, brain or mental disease\n\n          -  Subject allergic to any component of the investigational vaccine, or a more severe\n             allergic reaction and history of allergies in the past.\n\n          -  Woman who is pregnant, breast-feeding or positive in \u03b2-HCG (human chorionic\n             gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during\n             the next 6 months\n\n          -  Any acute fever disease or infections.\n\n          -  History of SARS\n\n          -  Major congenital defects or not well-controlled chronic illness, such as asthma,\n             diabetes, or thyroid disease.\n\n          -  Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial\n             infarction, severe hypertension without controllable drugs, etc.\n\n          -  Hereditary angioneurotic edema or acquired angioneurotic edema\n\n          -  Urticaria in last one year\n\n          -  No spleen or functional spleen.\n\n          -  Platelet disorder or other bleeding disorder may cause injection contraindication\n\n          -  Faint at the sight of needles.\n\n          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis\n             treatment, cytotoxic treatment in last 6 months.\n\n          -  Prior administration of blood products in last 4 months\n\n          -  Prior administration of other research medicines in last 1 month\n\n          -  Prior administration of attenuated vaccine in last 1 month\n\n          -  Prior administration of inactivated vaccine in last 14 days\n\n          -  Current anti-tuberculosis prophylaxis or therapy\n\n          -  According to the judgement of investigator,various medical, psychological, social or\n             other conditions, those could affect the subjects to sign informed consent."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "Accepts Healthy Volunteers"
        },
        "overall_official": {
            "last_name": "Fengcai Zhu, MD",
            "role": "Principal Investigator",
            "affiliation": "Jiangsu Province Centers of Disease Control and Prevention"
        },
        "overall_contact": {
            "last_name": "Wenjuan Wang, MD",
            "phone": "8625-83759911",
            "email": "wangwj@jscdc.cn"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 7, 2020",
        "study_first_submitted_qc": "April 9, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 10, 2020"
        },
        "last_update_submitted": "April 9, 2020",
        "last_update_submitted_qc": "April 9, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 10, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "COVID-19 vaccine",
            "Ad5-nCoV",
            "SARS-CoV-2"
        ],
        "condition_browse": {
            "mesh_term": [
                "Adenoviridae Infections",
                "Coronavirus Infections"
            ]
        },
        "intervention_browse": {
            "mesh_term": "Vaccines"
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}